Glycogen synthase kinase-3␤ (GSK-3␤) is a ubiquitously expressed constitutively active serine/threonine kinase that phosphorylates cellular substrates and thereby regulates a wide variety of cellular functions, including development, metabolism, gene transcription, protein translation, cytoskeletal organization, cell cycle regulation, and apoptosis. The activity of GSK-3␤ is negatively regulated by protein kinase B/Akt and by the Wnt signaling pathway. Increasing lines of evidence show that GSK-3␤ is an essential negative regulator of cardiac hypertrophy and that the inhibition of GSK-3␤ by hypertrophic stimuli is an important mechanism contributing to the development of cardiac hypertrophy. GSK-3␤ also plays an important role in regulating cardiac development. In this review, the role of GSK-3␤ in cardiac hypertrophy and development and the potential underlying mechanisms are discussed. (Circ Res. 2002;90:1055-1063.) 
T he signaling mechanisms leading to cardiac hypertrophy have been intensively investigated over the past decade. [1] [2] [3] [4] Identification of the signaling molecules necessary for the development of cardiac hypertrophy might lead to the development of therapeutic strategies to prevent or reverse the disease. During the past few years, mitogen-activated protein kinases (MAPKs), calcineurin (a Ca 2ϩ /calmodulindependent protein phosphatase), and Ca 2ϩ /calmodulindependent protein kinases have been intensively investigated because they positively regulate cardiac hypertrophy (see reviews 5, 6 ). Equally important in exploring the signaling mechanisms promoting hypertrophy is the dissection of pathways counteracting these prohypertrophic signaling mechanisms, which thereby alleviates the hypertrophic responses. Accumulating evidence suggests that glycogen synthase kinase-3␤ (GSK-3␤) negatively regulates cardiac hypertrophy and that the inhibition of GSK-3␤ by hypertrophic stimuli is an important mechanism in the stimulation of cardiac hypertrophy. [7] [8] [9] [10] [11] [12] GSK-3␤ also regulates cardiac development through its effect on Wnt signaling. In the present article, it is our goal to review recent findings regarding the role of GSK-3␤ in cardiac hypertrophy and development and to discuss the potential underlying mechanisms.
GSK-3␤ Is a Proline-Directed Serine/Threonine Protein Kinase Whose Activity Is Negatively Regulated by Multiple Mechanisms
GSK-3 belongs to a family of conserved serine/threonine kinases present in all eukaryotic groups. GSK-3 consists of two isoforms in humans, namely, GSK-3␣ (51 kDa) and
GSK-3␤ (47 kDa) (see reviews [13] [14] [15] ). GSK-3␣ and GSK-3␤ have 97% sequence homology within their kinase domains, whereas GSK-3␣ has an extended N-terminal glycine-rich tail. 16 Although both isoforms share substrates, their expression patterns, substrate preferences, and cellular functions are not identical. 15, 17 Kinase activities of GSK-3␣ and GSK-3␤ are regulated similarly in some cases 18 but differently in other cases. 19, 20 Although both isoforms are expressed in the heart, 21 most studies that have been conducted thus far have examined the role of GSK-3␤, possibly because of the general lack of specific reagents for GSK-3␣. Although GSK-3␤ was initially described for its function to inhibit glycogen synthesis through phosphorylation of glycogen synthase, 22, 23 it has been revealed that GSK-3␤ regulates a wide range of cellular functions, including metabolism, gene expression, and cytoskeletal integrity 13 (Figure  1 ). GSK-3␤ is also involved in a variety of disease processes, such as tumorigenesis and the development of Alzheimer's disease. 24 -26 The minimal recognition determinant for phosphorylation by GSK-3␤ has been identified as -S-P-X-X-S-, 27 where the first serine is phosphorylated by GSK-3␤. GSK-3␤ tends to phosphorylate serine/threonine residues situated N-terminally next to a proline and is thus considered to be a proline-directed kinase. 27, 28 The affinity of GSK-3␤ to some substrates is enhanced if the substrate is prephosphorylated at ϩ4 serine/threonine by other kinases (referred to as "priming kinases"), including protein kinase A, casein kinases (I␣ and II), and DYRK (which indicates dual-specificity tyrosinephosphorylated and -regulated kinase). 29 -31 When sequential overlapping GSK-3␤ sites are present, GSK-3␤ itself can act as its own priming kinase. 32 GSK-3-catalyzed phosphorylation of some substrates, such as the axin-adenomatous polyposis coli (APC)-␤-catenin complex, may not require priming phosphorylation. 33 GSK-3␤ is localized predominantly in the cytoplasm but is also found in the nucleus. Its subcellular localization is changed in response to stimuli. 9, 10, 34, 35 For example, endothelin-1 stimulates nuclear translocation, 10 whereas isoproterenol causes the nuclear exit of GSK-3␤ in cardiac myocytes. 9 Serum withdrawal causes a marked increase in nuclear GSK-3␤ in neuronal cells. 35 
Activation
An important characteristic of GSK-3 is the fact that it is catalytically active in cells even under unstimulated conditions. Thus, total cellular activities of GSK-3 may be predominantly regulated at the level of protein expression. Interestingly, however, phosphorylation of GSK-3 at Tyr216 can further increase its kinase activity. 36, 37 In Dictyostelium, stimulation of the cAMP receptor (CAR3) activates ZAK1, a non-receptor-type tyrosine kinase, which in turn phosphorylates and activates GskA, a homologue of mammalian GSK-3. 38 Tyrosine kinases homologous to ZAK1 may exist in higher eukaryotic organisms. 38
Inactivation
Because GSK-3␤ negatively regulates downstream signaling mechanisms, inactivation of GSK-3␤ in fact stimulates many cellular functions by removing the negative constraint imposed by GSK-3␤. The activity of GSK-3␤ is regulated by multiple mechanisms (Figure 1 ). Most importantly, inactivation of GSK-3␤ is induced by phosphorylation via upstream protein kinases (see review 33 ). The phosphorylation sites that lead to the inactivation of GSK-3 have been identified as Ser21 for GSK-3␣ and as Ser9 for GSK-3␤. 39 -41 Protein kinase B (PKB)/Akt is one of the most thoroughly studied of the kinases that have been identified as upstream regulators of GSK-3␤. Because PKB/Akt is a major kinase downstream from phosphatidylinositol 3-kinase (PI3K), many stimuli that activate PI3K inhibit GSK-3␤ through PKB/Akt. Morisco et al 8 have recently demonstrated that ␤-adrenergic stimulation activates PKB/Akt and inactivates GSK-3␤ in cardiac myocytes. Other cardiac hypertrophic stimuli, including endothelin-1, Fas, and pressure overload, also inhibit GSK-3␤, possibly through activation of the PI3K-PKB/Akt pathway. 10, 11 Other upstream protein kinases that inhibit GSK-3␤ include integrin-linked kinase (ILK), 42 protein kinase A, 43 protein kinase C␦, 44 protein kinase C, 45 p90 ribosomal S6 kinase, and p70 S6 kinase-1 46 (Figure 1 ). Interestingly, ILK induces phosphorylation of GSK-3␤ at an amino acid residue distinct from Ser9. 42 Activation of the Wnt signaling pathway (see below) is another important mechanism to inhibit activity of GSK-3␤. In the presence of Wnt, Dishevelled (Dvl) and FRAT (frequently rearranged in advanced T-cell lymphomas) disrupt interaction between GSK-3 and axin, thereby leading to inactivation of GSK-3 via mechanisms distinct from the phosphorylation of GSK-3 at the residue targeted by insulin. 47, 48 Although both insulin and Wnt pathways inactivate GSK-3␤, they regulate distinct targets: Insulin induces an increased activity of glycogen synthase but has no influence on the protein level of ␤-catenin. In contrast, Wnt increases the cytosolic pool of ␤-catenin but not glycogen synthase activity. 49 It has been suggested that GSK-3␤ phosphorylates ␤-catenin only when it is sequestered by the axin-APC complex. 15, 33 Besides endogenous regulators of GSK-3␤, several compounds directly inhibit kinase activities of GSK-3␤. LiCl is the most commonly used inhibitor of GSK-3␤. 50 SB-216763 and SB-415286, structurally distinct maleimides, are potent and selective cell-permeable inhibitors of GSK-3␤. 51
GSK-3␤ Inhibits Cardiac Hypertrophy In Vivo and In Vitro
Recent evidence shows that GSK-3␤ functions as a negative regulator of cardiac hypertrophy. [7] [8] [9] [10] [11] Increased cellular activities of GSK-3␤ by overexpression inhibit many aspects of cardiac hypertrophy, including increases in the rate of protein synthesis and hypertrophic gene expression. [7] [8] [9] [10] [11] Activation of the hypertrophic program by stimulation of ␤-adrenergic receptors, G q -coupled receptors, and Fas receptors leads to inactivation of endogenous GSK-3␤ via phosphorylation of Ser9, predominantly through the PI3K/Akt pathway. [7] [8] [9] [10] [11] This prevents endogenous GSK-3␤ from executing its inhibitory effects on hypertrophy, thereby stimulating hypertrophy. Cardiac-specific overexpression of a mutant form of GSK-3␤ (GSK-3␤S9A), which cannot be phosphorylated at Ser9, in transgenic mice inhibits hypertrophy in response to aortic banding and isoproterenol stimulation and partially prevents cardiac hypertrophy caused by an activated form of calcineurin. 7 Lack of Fas receptor-induced inhibition of GSK-3␤ by pressure overload in lpr mice, which do not have functional Fas receptors, causes rapid-onset left ventricular dilatation and heart failure that are due to the absence of compensatory hypertrophy. 11 Insulin-induced phosphorylation/inactivation of GSK-3␤ is impaired in diabetes. Resistance of GSK-3␤ phosphorylation by insulin may contribute not only to impaired glycogen synthesis but also to reduced protein synthesis, leading to the development of diabetic cardiomyopathy. 52 Because GSK-3␤ regulates nuclear transcription, protein translation, and cytoskeletal organization in other cell types, it is likely that GSK-3␤ affects cardiac hypertrophy and the development of cardiomyopathy through multiple mechanisms, as proposed in Figure 2 .
Regulation of Cardiac Transcription Factors
GSK-3␤ phosphorylates a wide variety of transcription factors, thereby regulating the nuclear transcription process. The Table  lists the transcription factors known to be phosphorylated by GSK-3␤ and summarizes how GSK-3␤-induced phosphorylation affects them. In general, phosphorylation of transcription factors by GSK-3␤ causes ubiquitination, nuclear exit, or decreases in the DNA binding, leading to decreases in nuclear transcription (Table) . However, in some transcription factors, such as C/EBP␣, CREB, and nuclear factor-B, phosphorylation by GSK-3␤ stimulates transcription. 17, 53, 54 Recent data from our laboratory show that GSK-3␤ directly phosphorylates GATA4 and negatively regulates transcription through GATA4 by stimulating Crm-1-mediated nuclear export of GATA4. 9 Members of the GATA family zinc finger transcription factors play an important role in mediating cardiac development 55, 56 and cardiac hypertrophy [57] [58] [59] [60] [61] (see review 62 ) . A number of genes whose expression is altered during cardiac hypertrophy, including atrial natriuretic factor (ANF), brain natriuretic peptide, ␣and ␤-myosin heavy chain, cardiac troponin I, platelet-derived growth factor receptor ␤, angiotensin II type 1a receptor, and Na ϩ -Ca 2ϩ exchanger, are critically regulated by GATA4 and other GATA family transcription factors. [57] [58] [59] [60] 63, 64 Thus, the regulation of GATA4 by GSK-3␤ should widely affect phenotypic changes of cardiac myocytes during cardiac hypertrophy. Morisco et al 8 have demonstrated that overexpression of either wild-type or Akt-insensitive GSK-3␤ negatively regulates the transcription of ANF in neonatal rat cardiac myocytes, whereas stimulation of the ␤-adrenergic receptors increases transcription of ANF through the inactivation of GSK-3␤. The induction of ANF expression by endothelin was markedly inhibited by overexpression of GSK-3␤S9A in cardiac myocytes. 10 Haq et al 10 have demonstrated that GSK-3␤ inhibits endothelin-1-induced hypertrophy in neonatal rat cardiac myocytes. GSK-3␤ maintains nuclear factors of activated T cells (NF-AT, an important positive mediator of cardiac hypertrophy 65 ) in the cytosol or delays endothelin-1-induced nuclear import of NF-AT, thereby preventing NF-AT-mediated nuclear transcription. Because nuclear localization of NF-AT is positively regulated through its dephosphorylation by calcineurin, 65 phosphorylation by GSK-3␤ acts as a counterregulatory mechanism against the calcineurin pathway. As with the stimulation of calcineurin, inhibition of GSK-3␤ by endothelin-1 causes nuclear translocation of NF-AT, thereby stimulating cardiac hypertrophy. Additional overexpression of GSK-3␤S9A in transgenic mice overexpressing an activated form of calcineurin significantly decreased the nuclear localization of NF-AT. 7 Whether stimulation of calcineurin or inhibition of GSK-3␤ predominates in the induction of cardiac hypertro-
Proposed mechanisms leading to antihypertrophic effects of GSK-3␤. Hypertrophic stimuli activate various signaling cascades leading to activation of the "hypertrophic program," which includes increase in myocyte size, increase in protein synthesis, and cytoskeletal organization. Ca 2ϩ /CaM indicates Ca 2ϩ /calmodulin; CaM kinase, Ca 2ϩ /calmodulindependent protein kinase; MEF2, myocyte-enhancer factor 2; MAP, microtubule-associated protein; eIF2B⑀, eukaryotic initiation factor 2B⑀; 4E-BP, eukaryotic initiation factor 4E-binding protein; and eEF2, eukaryotic elongation factor 2. phy seems to depend on the character of the hypertrophic stimulus. For example, inhibition of GSK-3␤ seems to predominate over the stimulation of calcineurin in the induction of ␤-adrenergic cardiac hypertrophy, inasmuch as inhibition of the calcineurin pathway with cyclosporin A only partially blocks ␤-adrenergic ANF transcription, whereas overexpression of GSK-3␤ completely blocks it in neonatal rat cardiac myocytes. 8 In contrast, both mechanisms may be equally important for endothelin-1-induced cardiac hypertrophy. 10 What is the importance of GSK-3␤ among the many signaling mechanisms known to promote cardiac hypertrophy? We speculate that the PI3K/PKB/Akt/GSK-3␤ pathway may be as important as the MAPK signaling mechanisms in some types of cardiac hypertrophy, such as G q -mediated hypertrophy. 10 However, the PI-3K/PKB/Akt/GSK-3␤ pathway can be the predominant mechanism when activation of the MAPK pathway is less prominent, such as in the case of ␤-adrenergic cardiac hypertrophy. 7, 8 
Effects of Phosphorylation by GSK-3␤ on Transcription Factors

Regulation of Protein Synthesis
Protein synthesis is a complex process involving three essential steps: initiation, elongation, and termination. 66 The concerted actions of multiple signaling molecules are required for the regulation of protein synthesis (see reviews 66, 67 ). One of the critical steps controlling the initiation of protein translation is the binding of eukaryotic translation initiation factor 2 (eIF2) to the activated initiator tRNA (met-tRNA met ) and subsequent formation of a ternary complex that binds to the 40S ribosomal subunit. eIF2B⑀ is the largest of the five subunits of eIF2B and is required for the GDP/GTP exchange reaction of eIF2. GSK-3␤ phosphorylates eIF2B⑀ at Ser540 and inactivates it. 68 Inactivation of GSK-3␤ by cell growth stimuli leads to decreases in the phosphorylation and activation of eIF2B⑀, which promotes the initiation of protein synthesis.
Haq et al 10 have demonstrated that overexpression of GSK-3␤S9A in neonatal rat cardiac myocytes blocks development of the key features of cardiac hypertrophy, including increases in the rate of protein synthesis, on G␣ q -coupled receptor stimulation. Overexpression of wild-type GSK-3␤ also inhibits increases in cell size as well as the total cellular protein content in cardiac myocytes in response to ␤-adrenergic stimulation in vitro (authors' unpublished data, 2002) and in response to pressure overload and ␤-adrenergic stimulation in vivo. 7 By contrast, inhibition of GSK-3␤ with LiCl increases protein synthesis. 10 The downstream signaling mechanism regarding how GSK-3␤ negatively affects protein synthesis in cardiac myocytes remains to be investigated. Inhibition of protein translation initiation through the phosphorylation of eIF2B⑀ may be one of the mechanisms in mediating the antihypertrophic effects of GSK-3␤. Alternatively, GSK-3␤ may transcriptionally regulate expression of the critical regulators for protein translation or autocrine/ paracrine factors. Inhibition of GSK-3␤ by hypertrophic stimuli is, in many cases, accompanied by the activation of PI3K and Akt, which also positively regulate other regulators of protein synthesis via the FK506-binding protein/rapamycin-associated protein/mammalian target of rapamycin pathway, including eukaryotic initiation factor 4E-binding pro-tein, p70 ribosomal S6 kinase-1, and eukaryotic elongation factor 2. 66, 67, 69 Therefore, it is likely that GSK-3␤ works in concert with other molecules downstream from PI3K/Akt to regulate protein synthesis during cardiac hypertrophy.
Regulation of Cytoskeletal Organization
GSK-3␤ has been shown to phosphorylate microtubuleassociated proteins (MAPs), including tau, MAP2c, and MAP1B, thereby contributing to cytoskeletal remodeling events in many cell types. 70 -72 Neurofibrillary tangles of paired helical filaments are neuropathological hallmarks of Alzheimer's disease, and abnormally phosphorylated tau is the major subunit of paired helical filaments. 73 Phosphorylation of tau inhibits microtubule assembly and reduces its ability to stabilize microtubules. Inhibition of GSK-3␤ by hypertrophic stimuli potentially affects microtubules and other cytoskeletal structures of cardiac myocytes through its effects on ␤-catenin and microtubule-associated proteins. Overexpression of GSK-3␤S9A inhibits endothelin-1induced actin reorganization in neonatal rat cardiac myocytes. 10
Regulation of Cell Cycle
Temporal and spatial expression and activation of the cell cycle regulators, including cyclins and cyclin-dependent kinases (cdks), are tightly regulated to control the cell-cycle transition. 74 Among many cell-cycle regulators, cyclin D1, a regulator of G 1 -to S-phase transition, is a critical downstream target of the Wnt1 signaling. 75 It is expected that GSK-3␤ negatively regulates cyclin D1 expression by inhibiting the Wnt1 signaling. In addition, activity and nuclear localization of GSK-3␤ are regulated in a cell-cycle-dependent manner, which, in turn, controls subcellular localization and expression of cyclin D1 through phosphorylation of Thr286. 34 Phosphorylation of cyclin D1 by GSK-3␤ causes increased association of cyclin D1 with a nuclear exportin (Crm-1) and promotes nuclear exit and subsequent proteasomal degradation of cyclin D1. 76 Because the cyclin-cdk complex has recently been implicated in various cellular functions in cardiac myocytes not restricted to DNA synthesis 77, 78 (see reviews 79, 80 ) GSK-3␤-induced regulation of cyclin D1 may be involved in cell growth/death responses in the heart. GSK-3␤ phosphorylates p21 Cip1 , thereby stimulating its degradation in human umbilical vein endothelial cells. 81 Interestingly, inhibition of GSK-3␤ by LiCl causes accumulation of p21 Cip1 and hypertrophy of endothelial cells. 81
Regulation of Apoptosis
GSK-3␤ plays an important role in the regulation of apoptosis/cell survival. GSK-3␤ promotes apoptosis in neuronal cells 82, 83 and vascular smooth muscle cells. 84 Increased cAMP levels promote survival of neuronal cells by inactivating GSK-3␤ via a protein kinase A-dependent mechanism. 83 Overexpression of a mutant form of eIF2B⑀, which cannot be phosphorylated by GSK-3␤, inhibits cytochrome c release in PC12 cells, 85 suggesting that apoptosis by GSK-3␤ is mediated by the phosphorylation of eIF2B⑀. GSK-3␤ inhibits antiapoptotic molecules, including heat shock factor-1 and the associated expression of heat shock protein-70, 86, 87 which may, in turn, stimulate apoptosis.
By contrast, findings in other cell types suggest that GSK-3␤ mediates cell survival. For example, GSK-3␤ knockout mice die in utero with increased apoptosis in the liver caused by excessive production of tumor necrosis factor, suggesting that GSK-3␤ mediates cell survival mechanisms, such as activation of nuclear factor-B. 17 Furthermore, ␤-catenin promotes apoptosis in some mammalian cell lines. 88 In this case, GSK-3␤ should inhibit apoptosis through the degradation of ␤-catenin.
Collectively, whether GSK-3␤ promotes apoptosis or cell survival depends on the cell types. It has been shown that PKB/Akt promotes cell survival in cardiac myocytes. 89 The cell survival effect of Akt may be partially mediated by phosphorylation/inhibition of GSK-3␤. It has been suggested that calcineurin promotes cell survival in cardiac myocytes. 90 It is of great interest to determine whether GSK-3␤ counteracts the antiapoptotic effect of calcineurin and promotes apoptosis in cardiac myocytes.
Regulation of Wnt Signaling Pathway by GSK-3␤ and Its Role in Cardiac Development and Postnatal Hearts
Wnt/Wingless proteins are a family of cysteine-rich glycoproteins that regulate cell fate decisions, embryonic development, 91 and tumorigenesis. 92 Association of Wnt and the Frizzled (Fz) family of transmembrane receptors leads to accumulation of ␤-catenin, a key downstream target of Wnt signaling 93 (Figure 3 ). GSK-3␤ is a critical regulator of this signaling mechanism. GSK-3␤ forms a complex with axin (and its close relative conductin) and the tumor suppressor gene product APC. This complex, called the destruction complex, controls the stability of ␤-catenin. Axin is a scaffold molecule and sequesters GSK-3 ␤ in this complex. 15 When GSK-3␤ is active, it phosphorylates APC and ␤-catenin and stimulates interaction between ␤-catenin and ␤-Trcp, a regulator of E3 ubiquitin ligase, and subsequent degradation of ␤-catenin in proteasomes. 94, 95 Binding of the Wnt molecules to Fz receptors activates Dvl, which inhibits the activity of GSK-3␤, 96 thereby stabilizing ␤-catenin. 97 Casein kinase I⑀ also makes a complex with axin, GSK-3␤, and Dvl and works as a positive regulator of the Wnt signaling. 98 Stabilization of ␤-catenin is associated with its translocation to the nucleus, where it interacts with members of the lymphoid enhancer factor (LEF)/T-cell factor (TCF) and activates specific target genes. 99, 100 It should be noted that inhibition of GSK-3␤ alone is not sufficient to activate LEF/TCF and that an additional factor is required to facilitate dissociation of GSK-3␤ from axin. 101
GSK/Wnt Signaling in Cardiac Development
Accumulating evidence shows that the components of the Wnt pathway play a significant role in heart development. Several recent studies have shown that the Wnt signaling pathway negatively regulates cardiogenesis. [102] [103] [104] [105] For example, in Xenopus, Wnt3a and Wnt8 inhibit heart induction, and ectopic expression of GSK-3␤ induces cardiogenesis in ventral mesoderm. 103 The secreted Wnt antagonists crescent and Dickkopf-1 are expressed in the anterior mesoderm and promote cardiogenesis by interfering with the Wnt signaling pathway. 104 Similarly, inhibition of Wnt activity induces heart formation from the posterior mesoderm in chick embryos. 105 In contrast to these findings, other reports suggest that the Wnt signaling positively regulates cardiac development. For example, wingless, zeste-white3/shaggy-encoded kinase, and armadillo, the Drosophila homologues of Wnt, GSK-3␤, and ␤-catenin, respectively, have been shown to play a crucial role in specifying the heart progenitors in Drosophila. 106, 107 In chicks, the ectopic expression of Wnt11 has been shown to promote cardiac development within noncardiac tissue. 108 It should be noted that the effect of Wnt11 may be mediated by protein kinase C and Ca 2ϩ /calmodulin-dependent protein kinase II, not via GSK-3␤ and ␤-catenin. 109 ␤-Catenin is involved in the initial differentiation of the heart-forming mesoderm in the chick embryo. 110, 111 Oral treatment with lithium, a mood-stabilizing drug that is inhibitory for GSK-3, in pregnant women showed a higher incidence of congenital heart defects in babies. 112 Collectively, GSK-3␤ is involved in heart development via the Wnt signaling pathway, yet the exact mechanisms of action remain to be elucidated.
Wnt Signaling in Postnatal Hearts
The Wnt signaling pathway may play a role in postnatal hearts as well. Wnt proteins, including Wnt10B, are expressed in the adult heart. 113 The Fz class of cell surface receptors for Wnt proteins, including Fz1 and Fz2, are expressed in human myocardium. 114 In myofibroblasts of infarcted hearts, Fz2 expression is considerably enhanced. 115 In failing ventricles of humans, mRNA levels of secreted Fz-related proteins 3 and 4, which are endogenous Wnt antagonists, are elevated, and the Wnt/␤-catenin pathway is attenuated. 116 However, the functional role of Wnt signaling in the normal and pathological hearts remains to be elucidated. When the Wnt signaling is activated and/or the kinase activity of GSK-3␤ is inhibited, ␤-catenin is stabilized and translocated into the nucleus, and it participates in the transcription process. 99, 117, 118 Stabilized ␤-catenin markedly stimulates the transcription of connexin43, a major component of cardiac gap junction channels. 119 Although ␤-catenin stimulates a reporter gene containing the consensus TCF binding sequence, 26 the nuclear transcription factor that ␤-catenin binds, presumably a member of the LEF/TCF family, has not been identified in cardiac myocytes.
Recent evidence suggests that ␤-catenin is upregulated in human hypertrophy. 120 Preliminary results from our laboratory also indicate that ␤-adrenergic stimulation of neonatal rat cardiac myocytes upregulates the expression of ␤-catenin. 121 Because the ␤-catenin-LEF/TCF complex controls the activities of many genes mediating cell proliferation, it will be interesting to elucidate how ␤-catenin affects cardiac hypertrophy. The Wnt signaling pathway also activates ␤-cateninindependent signaling mechanisms. For example, Dvl activates c-Jun NH 2 -terminal kinases, 122 which may stimulate cardiac hypertrophy.
Because ␤-catenin is a central component of the cadherincell adhesion complex, it is speculated that ␤-catenin also directly affects the formation of cell-cell junctions independently of its role as a transcriptional regulator. In fact, the Wnt-Fz2 signaling pathway is involved in the stabilization of the cadherin-␤-catenin complex in neonatal rat cardiac myocytes. 123 Chronic aortic stenosis in guinea pigs causes translocation of ␤-catenin and vinculin away from intercalated disks in failing myocytes, thereby impairing the mechanical linkage between N-cadherin and thin filaments and adversely affecting myocyte morphology. 124 It is of great interest to determine whether the activity of GSK-3␤ is altered in this animal model. Collectively, these results suggest that GSK-3␤ may affect cadherin-mediated cellular responses of cardiac myocytes through the regulation of ␤-catenin.
Unanswered Questions: Future Perspectives
As we have summarized in this review, GSK-3␤ regulates various cellular phenomena relevant for the growth and death of cardiac myocytes. Because overexpression of constitutively active GSK-3␤ suppresses the development of hypertrophy in vivo 7 and in vitro 8 -11 and because the activity of GSK-3␤ is negatively regulated by cardiac hypertrophic stimuli, 7-12 inhibition of GSK-3␤ by hypertrophic stimuli represents an important signaling mechanism of cardiac hypertrophy. This signaling mechanism is unique among major hypertrophic signaling pathways because "disinhibition" mediates the positive mechanism. Although several downstream signaling molecules, including GATA4, NF-AT, eIF2B⑀, and ␤-catenin, are likely to be regulated by GSK-3␤ in cardiac myocytes, the precise downstream signaling mechanisms regarding how GSK-3␤ negatively affects cardiac hypertrophy remain to be determined.
It has been shown that GSK-3␤ is phosphorylated and that its kinase activities are downregulated in patients with heart failure. 12 Although overexpression of GSK-3 ␤ (S9A) pre-vents pressure overload-induced cardiac hypertrophy in transgenic mice, 7 recent evidence suggests that the inhibition of GSK-3 ␤ is cardioprotective against ischemia. 125 Whether or not restoring GSK-3␤ activity in patients with heart failure is salutary remains to be elucidated. Other important unanswered questions include the following: What is the unique function of GSK-3␣ in the heart? Does GSK-3␤ play an important role in mediating physiological forms of cardiac hypertrophy, such as exercise-induced and pathophysiological changes of the heart during aging? Do calcineurin and GSK-3␤ always counterregulate the phosphorylation status of the same target molecules? Does GSK-3␤ promote apoptosis in cardiac myocytes? What are the other functions of GSK-3␤ in the heart?
Some useful tools to address these issues, including adenoviral vectors harboring wild types and mutants of GSK-3␤ as well as transgenic mice with cardiac specific overexpression of GSK-3␤ (S9A), are available. 7, 9, 10 Disruption of the murine GSK-3␤ gene results in embryonic lethality by severe liver degeneration. 17 To obtain genetic evidence regarding whether GSK-3␤ is required for postnatal cardiac disease, cardiac-specific knockout models will be required. To test the therapeutic potential of modulating GSK-3␤ in patients with heart failure, the effect of conditional expression or deletion of GSK-3␤ needs to be evaluated in animal models. It is expected that more evidence will become available in the near future to further dissect the underlying mechanisms by which GSK-3␤ regulates the growth and death of cardiac myocytes.
Note Added in Proof
Recently, Liu et al 136 have shown that priming phosphorylation of ␤-catenin by casein kinase I␣ is required for its subsequent phosphorylation by GSK-3␤ and degradation.
